Aptamers: An Emerging Tool for Diagnosis and Therapeutics in Tuberculosis

Srivastava, Shruti; Abraham, Philip; Mukhopadhyay, Sangita

doi:10.3389/fcimb.2021.656421

Cited by 18 publications

(19 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tuberculosis (TB), induced by M. tb , is one of the biggest health challenges in the world. Currently, about 1/3 of the population across the world are influenced by M. tb , and WHO speculated that approximately 10 million death cases were induced by TB in 2018 28 . As for TB diagnosis, smear microscopy is a simple and rapid detection method, whereas its positive rate is merely 50%~60%, 29,30 hence it is far from meeting clinical needs.…”

Section: Applications Of Aptamersmentioning

confidence: 99%

Aptamers: A prospective tool for infectious diseases diagnosis

Chen

Zhou

Peng

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

It is well known that people's health is seriously threatened by various pathogens (such as Mycobacterium tuberculosis, Treponema pallidum, Novel coronavirus, HIV, Mucor, etc.), which leads to heavy socioeconomic burdens. Therefore, early and accurate pathogen diagnosis is essential for timely and effective therapies. Up to now, diagnosing human contagious diseases at molecule and nano levels is remarkably difficult owing to insufficient valid probes when it comes to determining the biological markers of pathogens. Aptamers are a set of high‐specificity and high‐sensitivity plastic oligonucleotides screened in vitro via the selective expansion of ligands by exponential enrichment (SELEX). With the advent of aptamer‐based technologies, their merits have aroused mounting academic interest. In recent years, as new detection and treatment tools, nucleic acid aptamers have been extensively utilized in the field of biomedicine, such as pathogen detection, new drug development, clinical diagnosis, nanotechnology, etc. However, the traditional SELEX method is cumbersome and has a long screening cycle, and it takes several months to screen out aptamers with high specificity. With the persistent development of SELEX‐based aptamer screening technologies, the application scenarios of aptamers have become more and more extensive. The present research briefly reviews the research progress of nucleic acid aptamers in the field of biomedicine, especially in the diagnosis of contagious diseases.

show abstract

Section: Applications Of Aptamersmentioning

confidence: 99%

Aptamers: A prospective tool for infectious diseases diagnosis

Chen

Zhou

Peng

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…selected aptamer 1, which is specific to the hemagglutinin (HA) protein of the H1N1 influenza virus and can inhibit virus-induced hemagglutination and proliferation in host cells (Li et al., 2016 ). Additionally, several other aptamers have been developed as therapeutics for the treatment of Mycobacterium tuberculosis , HIV, human papilloma virus, and SARS-CoV-2 via mechanisms impairing the function of target proteins (Nicol et al., 2013 ; Srivastava et al., 2021 ; Sun et al., 2021 ; Ratanabunyong et al., 2022 ). Hence, the use of aptamers as inhibitors is a promising development with potentially extensive therapeutic benefits.…”

Section: Introductionmentioning

confidence: 99%

Targeted inhibition of methicillin-resistant Staphylococcus aureus biofilm formation by a graphene oxide-loaded aptamer/berberine bifunctional complex

et al. 2022

View full text Add to dashboard Cite

Biofilm formation is known to promote drug resistance in methicillin-resistant Staphylococcus aureus (MRSA), which is closely related to persistent infections in hospital settings. In this study, a DNA aptamer specific to penicillin-binding protein 2a (PBP2a) with a dissociation constant ( K d ) of 82.97 ± 8.86 nM was obtained after 14 cycles of systematic evolution of ligands by exponential enrichment (SELEX). Next, a bifunctional complex containing the aptamer intercalated by berberine into the double-strand region was prepared and adsorbed onto the surface of graphene oxide ( GO) by π-stacking interactions. The GO-loaded aptamer/berberine bifunctional complex showed significantly higher inhibition of MRSA biofilm formation than the control. Furthermore, this study shows that the complex possesses anti-biofilm activity, which can be attributed to the ability of the aptamer to reduce cell-surface attachment by blocking the function of PBP2a and berberine to attenuate the level of the accessory gene regulator ( agr ) system, which plays an important role in mediating MRSA biofilm formation. Therefore, the simultaneous delivery of berberine and PBP2a-targted aptamer using GO may have potential for the treatment of chronic infections caused by MRSA biofilms. It also provides a new avenue for multitarget treatment of bacterial biofilms.

show abstract

“…The development of TB immunodiagnostic tests like the tuberculin skin test (TST) and the interferon gamma release assay (IGRA) offers an alternative to sputum by assessing the peripheral immune response for the identi cation of individuals infected with Mtb but, these tests lack accuracy to monitor treatment. Diagnostic approaches based on non-sputum based tests like the evaluation of host plasma protein, transcriptomic or phenotypic signatures for treatment monitoring, screening or triage showed some relevant clinical advantages [5][6][7][8][9][10][11] .…”

Section: Introductionmentioning

confidence: 99%

Plasma host protein signatures correlating with Mycobacterium tuberculosis activity prior to and during antituberculosis treatment

Ndiaye

Ranaivomanana

Rasoloharimanana

et al. 2022

Preprint

View full text Add to dashboard Cite

Background There is a need for rapid non-sputum-based tests to identify and treat patients infected with Mycobacterium tuberculosis (Mtb). In this study, performance of a human plasma protein signature for both TB triage and treatment monitoring has been evaluated. Methods A panel of seven host proteins CLEC3B, SELL, IGFBP3, IP10, CD14, ECM1 and C1Q were measured in the plasma of a prospective patient cohort undergoing anti-tubercular therapy to distinguish confirmed TB patients from control, to define culture slow and fast converters during an antituberculosis treatment and to monitor the treatment. To validate the protein signatures a Luminex xMAP® assay was used to quantify the proteins in unstimulated plasma isolated from the blood collected from HIV-negative pulmonary TB patients (ATB), at baseline and following 6-months of antituberculosis treatment, latently TB-infected individuals (LTBI) and healthy donors (HD). Protein signatures performances were evaluated using CombiROC algorithm and multivariate models. Findings: We measured the proteins in the plasma of 84 participants including 37 ATB, 24 LTBI and 23 HD. The seven plasma host proteins studied showed different levels between the TB clinical groups and when used separately or in combination, have variable performances for ATB triage and for treatment monitoring. Six of the plasma proteins (CLEC3B, SELL, IGFBP3, IP10, CD14 and C1Q) showed significant differences in normalised median fluorescence intensities when comparing ATB vs HD or LTBI while ECM1 revealed a significant association with early sputum culture conversion after 2 months following treatment (OR 0.004, p = 0.018). For both triage and treatment monitoring, a signature combining 4 host proteins markers (CLEC3B-ECM1-IP10-SELL) was identified, allowing to distinguish ATB from HD or LTBI (respectively, sensitivity = 94%, specificity = 92% and sensitivity = 89%, specificity = 91%) as well as the baseline distinction between slow vs fast sputum culture converters after two months of treatment (AUC = 0.87, sensitivity = 83%, specificity = 84%). Conclusion Our data demonstrate that using a combination of host plasma markers can generate a relevant biosignature for both TB triage and treatment monitoring meeting the WHO Target Product Profile for both purposes.

show abstract

Aptamers: An Emerging Tool for Diagnosis and Therapeutics in Tuberculosis

Cited by 18 publications

References 116 publications

Aptamers: A prospective tool for infectious diseases diagnosis

Aptamers: A prospective tool for infectious diseases diagnosis

Targeted inhibition of methicillin-resistant Staphylococcus aureus biofilm formation by a graphene oxide-loaded aptamer/berberine bifunctional complex

Plasma host protein signatures correlating with Mycobacterium tuberculosis activity prior to and during antituberculosis treatment

Contact Info

Product

Resources

About